GILD
Gilead Sciences IncNASDAQ
Healthcare • Drug Manufacturers - General
Factor tilt: Mega-Cap Growth
$166.89-0.41%
Close Nov 6, 2026
- Market cap
- $207.21B
- 1 month
- +13.5%
- 3 months
- +25.4%
- 1 year
- +36.1%
- 52-week range
- $118.15$174.48
- Dividend, last 12 mo
- $3.25 · 1.95% yield
- Last ex-date
- Sep 15, 2026 · $0.82
- Dividend growth
- 10+ years in a row
- Short interest
- 1.6% of float20.3M shares · settled Oct 15, 2026 · -7.1% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Sep 30, 2026
- Revenue
- $30.99B
- Net income
- -$3.86B
- Free cash flow
- $14.04B
- Book value
- $13.04B
- Total debt
- $26.23B
- P/E
- —
- Price / sales
- 6.7×
- Price / book
- 15.9×
- FCF yield
- +6.8%
- Net margin
- -12.5%
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
Read more
It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.
- Website
- gilead.com
- Headquarters
- Foster City, CA, United States
- Employees
- 17,000
- Listed
- Jan 22, 1992
- Fiscal year ends
- December
Company profile from EODHD, stored Nov 1, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Sep 2026filed Oct 30, 2026 | $8.3B | +6.8% | 81.1% | $3.5B | $2.4B |
| Jun 2026filed Aug 6, 2026 | $7.8B | +10.2% | 79.8% | -$10.4B | -$10.5B |
| Mar 2026filed May 7, 2026 | $7.0B | +4.4% | 79.2% | $2.7B | $2.0B |
| Dec 2025filed Feb 24, 2026 | $7.9B | +4.7% | 79.5% | $3.0B | $2.2B |
| Sep 2025filed Nov 7, 2025 | $7.8B | +3.0% | 79.8% | $3.3B | $3.1B |
| Jun 2025filed Aug 7, 2025 | $7.1B | +1.8% | 78.8% | $2.5B | $2.0B |
| Mar 2025filed May 7, 2025 | $6.7B | -0.3% | 76.9% | $2.2B | $1.3B |
| Dec 2024filed Feb 28, 2025 | $7.6B | +6.4% | 79.1% | $2.5B | $1.8B |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Feb 24, 2026 | $29.4B | +2.4% | 78.8% | $11.7B | $8.5B |
| Dec 2024filed Feb 28, 2025 | $28.8B | +6.0% | 78.3% | $1.7B | $480.0M |
| Dec 2023filed Feb 6, 2024 | $27.1B | -0.6% | — | $7.6B | $5.7B |
| Dec 2022filed Feb 22, 2023 | $27.3B | -0.1% | 79.3% | $7.3B | $4.6B |
| Dec 2021filed Feb 23, 2022 | $27.3B | +10.6% | 75.8% | $9.9B | $6.2B |
| Dec 2020filed Feb 25, 2021 | $24.7B | +10.0% | 81.5% | $4.1B | $123.0M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched GILD. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
20,270,007 shares short
-1,558,718 shares (-7.1%) vs Sep 30, 2026
1.6% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
21,828,725 shares short
+3,523,850 shares (+19.3%) vs Sep 15, 2026
1.8% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
18,304,875 shares short
-4,702,154 shares (-20.4%) vs Aug 31, 2026
Share of float unavailable. Published Sep 24, 2026.
Settlement Aug 31, 2026
23,007,029 shares short
-176,941 shares (-0.8%) vs Aug 14, 2026
1.9% of the stored float. Published Sep 10, 2026.
Settlement Aug 14, 2026
23,183,970 shares short
-1,201,651 shares (-4.9%) vs Jul 31, 2026
1.9% of the stored float. Published Aug 25, 2026.
Settlement Jul 31, 2026
24,385,621 shares short
-876,290 shares (-3.5%) vs Jul 15, 2026
2% of the stored float. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind GILD’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
USD 0.82 per share
Ex-dividend date: Dec 15, 2026 (future recorded date)
Recorded pay date: Dec 30, 2026 (pending)
Cash dividend · Polygon event record
USD 0.82 per share
Ex-dividend date: Sep 15, 2026
Recorded pay date: Sep 29, 2026 (past date)
Cash dividend · Polygon event record
USD 0.82 per share
Ex-dividend date: Jun 15, 2026
Recorded pay date: Jun 29, 2026 (past date)
Cash dividend · Polygon event record
USD 0.82 per share
Ex-dividend date: Mar 13, 2026
Recorded pay date: Mar 30, 2026 (past date)
Cash dividend · Polygon event record
USD 0.79 per share
Ex-dividend date: Dec 15, 2025
Recorded pay date: Dec 30, 2025 (past date)
Cash dividend · Polygon event record
USD 0.79 per share
Ex-dividend date: Sep 15, 2025
Recorded pay date: Sep 29, 2025 (past date)
Cash dividend · Polygon event record
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
2 for 1 · forward split
Effective Jan 28, 2013
Each 1 pre-split share becomes 2 post-split shares.
Source: EODHD
2 for 1 · forward split
Effective Jun 25, 2007
Each 1 pre-split share becomes 2 post-split shares.
Source: EODHD
2 for 1 · forward split
Effective Sep 7, 2004
Each 1 pre-split share becomes 2 post-split shares.
Source: EODHD
2 for 1 · forward split
Effective Mar 8, 2002
Each 1 pre-split share becomes 2 post-split shares.
Source: EODHD
2 for 1 · forward split
Effective Feb 22, 2001
Each 1 pre-split share becomes 2 post-split shares.
Source: EODHD
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if GILD is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
293 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Nov 3, 2026
Smart-money 13F trend: accumulating (heavy)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: bearish
Last trade: sell 1 days ago
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 11
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
2,299 filers reported a long position in GILD for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
47.8%
of the 1.1B shares 13-F filers reported
Moves vs Q1 2026
7 added3 trimmed
Net shares held
+0.5%
across the 10 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | BlackRock, Inc. | $15.4B · 121.8M shares | 121.8M | +2.4% |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | $10.2B · 81.1M shares | 81.1M | +0.5% |
| 3 | FMR LLC | $8.4B · 66.9M shares | 66.9M | -7% |
| 4 | STATE STREET CORP | $7.7B · 61.2M shares | 61.2M | +2.3% |
| 5 | Capital World Investors | $5.2B · 41M shares | 41M | -0.7% |
| 6 | Invesco Ltd. | $5B · 39.8M shares | 39.8M | -4.2% |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | $4.5B · 35.3M shares | 35.3M | +0.5% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | $3.8B · 30.1M shares | 30.1M | +1.1% |
| 9 | PRICE T ROWE ASSOCIATES INC /MD/ | $3.8B · 30M shares | 30M | +14.3% |
| 10 | MORGAN STANLEY | $3B · 24M shares | 24M | +3% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of GILD file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Apr 29, 2026 | VANGUARD CAPITAL MANAGEMENT LLC13G · passive | 7.51% |
| Mar 26, 2026 | VANGUARD GROUP INC13G · passive · amended | 0%under 5% |
Get the Full Analysis for GILD
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.